Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Mounjaro may cause mood changes in some users due to shifts in gut-brain hormones, nutrition and hydration imbalances, blood sugar fluctuations, and rapid weight loss that can mimic depression. Whether to continue Mounjaro or switch therapies depends on careful symptom tracking, dose adjustments, and working with your healthcare provider on supportive strategies.
Because mood symptoms overlap with many other conditions—ranging from nutrient deficiencies to thyroid issues to clinical depression—identifying the true cause matters before changing your treatment plan. Take a free, instant, online symptom check to clarify what may be driving your symptoms and confidently plan your next steps with your doctor.
Reviewed for medical accuracy: 07/10/2026
Quick answers
The most common questions people search after this page
Mounjaro (tirzepatide) is a novel medication approved for type 2 diabetes and widely prescribed off-label for weight management. As with any drug that affects metabolism, appetite, and gut hormones, some patients report experiencing mood changes—including feelings of depression. Understanding why this happens, how common it is, and what steps to take can help you make informed decisions about your treatment.
While outright depression is not listed as a common side effect in major prescribing guides, several biological and lifestyle factors related to Mounjaro use may contribute to low mood:
Neurochemical Effects
Nutritional and Hydration Changes
Blood Sugar Fluctuations
Rapid Weight Loss and Body Image
Gut-Brain Axis Modulation
Keep an eye on mood and behavior changes, especially if they coincide with dose increases or severe GI side effects:
• Persistent sadness or tearfulness
• Loss of interest in usual activities
• Appetite changes unrelated to dosing schedule
• Trouble sleeping or excessive sleep
• Difficulty concentrating or making decisions
• Thoughts of self-harm or hopelessness
If you notice any of the above—especially suicidal thoughts—seek help immediately.
Deciding whether to continue Mounjaro or switch to another therapy involves weighing benefits (improved glycemic control, weight loss) against potential mental health risks. Here's a step-by-step approach:
Monitor and Document
Discuss with Your Doctor
Explore Supportive Measures
Evaluate Alternative Treatments
Mental Health Support
If switching becomes necessary, these classes of medications can be considered—always under professional guidance:
• Semaglutide (Ozempic, Wegovy)
• Liraglutide (Victoza)
• DPP-4 inhibitors (e.g., sitagliptin)
• SGLT2 inhibitors (e.g., empagliflozin)
• Basal insulin formulations
Each has its own benefit–risk profile. Your provider will tailor choices to your medical history, weight-loss goals, and mental health status.
If you're uncertain whether what you're feeling is a side effect of Mounjaro or a separate issue, take a moment to use this free AI symptom checker to understand what might be causing your symptoms and get guidance on whether you should see a doctor right away.
Always treat certain signs as emergencies:
If you experience these, call emergency services or go to the nearest emergency department.
Mounjaro has transformed diabetes care and weight management for many people. However, any report of depression or significant mood changes warrants attention. By tracking symptoms, working closely with your healthcare team, and exploring supportive strategies, you can find the safest, most effective treatment path.
If you ever feel that your mental health or physical safety is at risk, speak to a doctor right away. Your wellbeing—both body and mind—comes first.
(References)
* Li H, Wang K, Zhu C, Zhang X. Tirzepatide for type 2 diabetes and obesity: a comprehensive review of its efficacy and safety. J Clin Transl Endocrinol. 2023 Nov 28;33:100346. PMID: 38046467
* Zhang X, Li Z, Zhang X, Li H. Effect of glucagon-like peptide-1 receptor agonists on depression in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Metab Syndr Obes. 2022 Dec 21;15:3953-3965. PMID: 36582498
* Yang D, Luo J, Fang J, Xu X, Wu Y, Yang J, Yang T, Yang X. Glucagon-like peptide-1 receptor agonists and risk of psychiatric events: a real-world study. Diabetes Obes Metab. 2023 Jun;25(6):1709-1718. PMID: 36720498
* Han J, Shen M, Xu X, Yang J, Song D. Impact of tirzepatide on health-related quality of life and patient-reported outcomes in adults with obesity or overweight with weight-related comorbidities: a systematic review and meta-analysis. Obesity (Silver Spring). 2024 Mar;32(3):570-584. PMID: 38230752
* Zhang X, Yuan Y, Wang H, Wang Q, Zhang C, Hou C, Zhang C. Analysis of adverse events associated with tirzepatide: A real-world post-marketing safety study based on the FDA Adverse Event Reporting System (FAERS) database. Front Pharmacol. 2023 May 17;14:1162319. PMID: 37274026
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.